Alkermes plc. Deferred Revenue Recognized
Alkermes plc. (ALKS) reported Deferred Revenue Recognized of -$2.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-02-25
- Alkermes plc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was -$953.00K.
- Alkermes plc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was -$208.00K.
- Alkermes plc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$3.35M.
- Alkermes plc. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was -$3.06M.
- Alkermes plc. contract with customer, liability, revenue recognized for fiscal 2025 was -$2.56M.
- Alkermes plc. contract with customer, liability, revenue recognized for fiscal 2024 was -$3.56M.
- Alkermes plc. contract with customer, liability, revenue recognized for fiscal 2023 was -$5.00M.
- Alkermes plc. contract with customer, liability, revenue recognized for fiscal 2022 was -$7.51M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$2.56M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$2.56M 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | -$1.98M 10-Q · filed 2025-07-29 | |||
| 2025-03-31 | -$953.00K 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | -$3.56M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | -$2.47M 10-Q · filed 2024-10-24 | |||
| 2024-06-30 | -$1.50M 10-Q · filed 2024-07-24 | |||
| 2024-03-31 | -$208.00K 10-Q · filed 2024-05-01 | |||
| 2023-12-31 | -$5.00M 10-K · filed 2025-02-12 | |||
| 2023-09-30 | -$4.79M 10-Q · filed 2023-10-25 | |||
| 2023-06-30 | -$4.10M 10-Q · filed 2023-07-26 | |||
| 2023-03-31 | -$3.35M 10-Q · filed 2023-04-26 | |||
| 2022-12-31 | -$7.51M 10-K · filed 2024-02-21 | |||
| 2022-09-30 | -$5.40M 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | -$4.90M 10-Q · filed 2022-07-27 | |||
| 2022-03-31 | -$3.06M 10-Q · filed 2022-04-27 | |||
| 2021-12-31 | -$6.08M 10-K · filed 2023-02-16 | |||
| 2021-09-30 | -$4.64M 10-Q · filed 2021-10-27 | |||
| 2021-06-30 | -$3.11M 10-Q · filed 2021-07-28 | |||
| 2021-03-31 | -$1.24M 10-Q · filed 2021-04-28 | |||
| 2020-12-31 | -$4.92M 10-K · filed 2022-02-16 | |||
| 2020-09-30 | -$3.05M 10-Q · filed 2020-10-29 | |||
| 2020-06-30 | -$2.36M 10-Q · filed 2020-07-29 | |||
| 2020-03-31 | -$859.00K 10-Q · filed 2020-04-29 | |||
| 2019-12-31 | -$2.54M 10-K · filed 2021-02-11 | |||
| 2019-09-30 | -$1.89M 10-Q · filed 2019-10-23 | |||
| 2019-06-30 | -$1.07M 10-Q · filed 2019-07-25 | |||
| 2019-03-31 | -$790.00K 10-Q · filed 2019-04-25 | |||
| 2018-12-31 | -$3.13M 10-K · filed 2020-02-13 | |||
| 2018-09-30 | $3.31M 10-Q · filed 2018-10-23 | |||
| 2018-06-30 | -$2.27M 10-Q · filed 2018-07-26 | |||
| 2018-03-31 | -$664.00K 10-Q · filed 2018-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |